Coherus Oncology, Inc. Common Stock (NASDAQ: CHRS) last traded at $1.42, up 7.58% on the session. The quote above updates while this page is open; the figures below are drawn from Coherus Oncology, Inc. Common Stock’s own filings and are restated only when a new one is published.
Coherus Oncology, Inc. Common Stock trades on NASDAQ under the ticker CHRS. Its market capitalisation is $219.39 million.
Valuation measures for Coherus Oncology, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $219.39M |
|---|---|
| Enterprise value | $266.81M |
| Price / sales | 4.31 |
| Price / book | 3.61 |
| Beta | 1.94 |
Trailing-twelve-month figures tagged in Coherus Oncology, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $50.94M |
|---|---|
| Net income (TTM) | -$132.13M |
| Operating margin | -311.56% |
| Return on equity | -217.19% |
| Cash | $82.92M |
Range and volume for CHRS over the past 52 weeks.
| 52-week high | $2.62 |
|---|---|
| 52-week low | $1.09 |
| Volume | 1.55M |
| Average volume | 1.01M |
| Previous close | $1.32 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.